Eli Lilly invests in Superluminal's $120M Series A round as AI-focused startups eye the clinic

Andrew Dunn

Senior Biopharma Correspondent

Superluminal Medicines joined the ranks of AI-focused biotechs hauling in megarounds, closing an RA Capital-led $120 million Series A, the startup said Monday.

The new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly invests in Superluminal's $120M Series A round as AI-focused startups eye the clinic

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Eli Lil­ly in­vests in Su­per­lu­mi­nal's $120M Se­ries A round as AI-fo­cused star­tups eye the clin­ic

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Eli Lilly invests in Superluminal's $120M Series A round as AI-focused startups eye the clinic

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?